L-Buthionine (S,R)-sulfoximine structure
|
Common Name | L-Buthionine (S,R)-sulfoximine | ||
---|---|---|---|---|
CAS Number | 83730-53-4 | Molecular Weight | 222.305 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 382.3±52.0 °C at 760 mmHg | |
Molecular Formula | C8H18N2O3S | Melting Point | 224-228ºC (dec.) | |
MSDS | USA | Flash Point | 185.0±30.7 °C |
Use of L-Buthionine (S,R)-sulfoximineL-Buthionine-(S,R)-sulfoximine is a cell-permeable, potent, fast acting and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC50 value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively. |
Name | l-buthionine-(s,r)-sulfoximine |
---|---|
Synonym | More Synonyms |
Description | L-Buthionine-(S,R)-sulfoximine is a cell-permeable, potent, fast acting and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC50 value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively. |
---|---|
Related Catalog | |
Target |
γ-glutamylcysteine synthetase[1]. |
In Vitro | L-Buthionine-(S,R)-sulfoximine (BSO: 50 μM) treatment for 48 hr results in a 95% decrease in ZAZ and M14 melanoma cell line GSH levels, and a 60% decrease in GST enzyme activity. GST-π protein and mRNA levels are significantly reduced in both cell lines[1]. L-Buthionine-(S,R)-sulfoximine (BSO) induces oxidative stress in a cell by irreversibly inhibiting g-glutamylcysteine synthetase, an essential enzyme for the synthesis of glutathione (GSH)[2]. |
In Vivo | The average number of eye-spots (mean±SEM) is 5.36±0.29 (n=46), 7.79±0.45 (n=34) and 8.78±0.61 (n=32) in untreated controls, 2 mM L-Buthionine-(S,R)-sulfoximine (BSO) and 20 mM BSO treated mice, respectively. The 2 mM BSO treatment results in ~30% more eye-spots, and the 20 mM treatment results in 40% more eye-spots compared with untreated mice. It is showed that BSO causes an elevated frequency of DNA deletions during mouse development. BSO treatment reduced GSH concentration in mouse fetuses by 55% and 70% at 2 mM and 20 mM BSO doses, respectively, compared to untreated mice. Co-treatment with 2 mM BSO and 20 mM NAC depleted GSH to a similar extent as 2 mM BSO, consistent with the function of BSO to inhibit the g-GCS enzyme indispensable for GSH synthesis. Like GSH, cysteine levels dropped following BSO treatment[2]. |
Animal Admin | Mice[2] C57BL/6J pun/pun mice are used in the study. Pregnancy is timed by checking for vaginal plugs. Noon of the day of discovery is counted as 0.5 days post coitum (d.p.c.). Similarly, the time of birth of a litter is timed with the noon of discovery counted as 0.5 days post-partum (d.p.p.). Pregnant dams are given free access to drinking water supplemented by either 2 mM L-Buthionine-(S,R)-sulfoximine (BSO), 20 mM BSO, 2 mM BSO and 20 mM NAC, 20 mM NAC or unsupplemented water for 18 days from 0.5 to 18.5 d.p.c. The pH of supplemented water is as follows: 6.88, 20 mM BSO; 3.37, 2 mM BSO; 2.65, 2 mM BSO plus 20 mM NAC; and 2.58, 20 mM NAC. The pH of regular water used in our facility is ~4. To determine the DNA deletion frequency, 20-day-old offspring (23 mice in the control group and 16-17 mice per exposure group) are sacrificed to visualize eye-spots (DNA deletions) in their RPE[2]. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 382.3±52.0 °C at 760 mmHg |
Melting Point | 224-228ºC (dec.) |
Molecular Formula | C8H18N2O3S |
Molecular Weight | 222.305 |
Flash Point | 185.0±30.7 °C |
Exact Mass | 222.103806 |
PSA | 112.62000 |
LogP | 0.22 |
Vapour Pressure | 0.0±1.9 mmHg at 25°C |
Index of Refraction | 1.538 |
Storage condition | 2~8°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
Hazard Codes | Xn |
Risk Phrases | R36/37/38 |
Safety Phrases | S22;S24/25 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
RTECS | EK7713440 |
HS Code | 2925290090 |
~% L-Buthionine (S... CAS#:83730-53-4 |
Literature: Chemical and Pharmaceutical Bulletin, , vol. 8, p. 177 - 182 |
Precursor 1 | |
---|---|
DownStream 0 |
HS Code | 2925290090 |
---|---|
Summary | 2925290090 other imines and their derivatives; salts thereof。Supervision conditions:None。VAT:17.0%。Tax rebate rate:9.0%。MFN tariff:6.5%。General tariff:30.0% |
Auranofin induces apoptosis and necrosis in HeLa cells via oxidative stress and glutathione depletion.
Mol. Med. Report. 11(2) , 1428-34, (2014) Auranofin (Au), an inhibitor of thioredoxin reductase, is a known anti‑cancer drug. In the present study, the anti‑growth effect of Au on HeLa cervical cancer cells was examined in association with le... |
|
Neutral sphingomyelinase-2 is a redox sensitive enzyme: role of catalytic cysteine residues in regulation of enzymatic activity through changes in oligomeric state.
Biochem. J. 465(3) , 371-82, (2015) Neutral sphingomyelinase-2 (nSMase-2) is the major sphingomyelinase activated in response to pro-inflammatory cytokines and during oxidative stress. It is a membrane-bound 655 amino acid protein conta... |
|
Glutathione metabolism in the HaCaT cell line as a model for the detoxification of the model sensitisers 2,4-dinitrohalobenzenes in human skin.
Toxicol. Lett. 237 , 11-20, (2015) Glutathione (GSH) is the most prominent antioxidant in cells and the co-factor of an important set of enzymes involved in the skin metabolic clearance system, glutathione S-transferases (GST). Here, w... |
L-BUTHIONINESULPHOXIMINE |
L-BUTHIONINE-S,R-SULPHOXIMINE |
Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-, (2S)- |
L-BUTHIONINE-SULFOXIMINE |
L-BUTHIONINE-[S,R]-SULFOXIME |
MFCD00067000 |
(2S)-2-Amino-4-(S-butylsulfonimidoyl)butanoic acid |
dl-S-(n-butyl)-homocystein-DR-sulfoximine |
buthionine-<S,R>-sulfoximine |
L-Buthionine (S,R)-sulfoximine |
D-Buthionine Sulfoximine |
D,L-buthionine-(S,R)-sulfoximine |
Buthionine sulfoximine |
L-BUTHIONINE (R,S)-SULFOXIMINE |
L-BSO |
DL-buthionine-(S,-R)-sulphoximine |